Drug Approval | September 21, 2021
U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
HTL will build, validate and operate a botulinum manufacturing facility in the US
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The company to receive upfront and milestone payments, in addition to royalties
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
